Page last updated: 2024-11-13

xk 469

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

XK 469: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23675947
CHEMBL ID2028299
SCHEMBL ID8881029
MeSH IDM0302995

Synonyms (20)

Synonym
xb 469
xk 469
157434-99-6
nsc-656889
unii-g6s5600o0d
sodium 2-(4-((7-chloro-2-quinoxalinyl)oxy)phenoxy)propionate
g6s5600o0d ,
nsc 656889
propanoic acid, 2-(4-((7-chloro-2-quinoxalinyl)oxy)phenoxy)-, sodium salt
SCHEMBL8881029
propanoic acid, 2-(4-((7-chloro-2-quinoxalinyl)oxy)phenoxy)-, sodium salt, (+/-)-
xk 469 [who-dd]
xb-469
CHEMBL2028299
sodium 2-(4-(7-chloro-2-quinoxalinyloxy)phenoxy)propionate
sodium;2-[4-(7-chloroquinoxalin-2-yl)oxyphenoxy]propanoate
sodium 2-{4-[(7-chloroquinoxalin-2-yl)oxy]phenoxy}propanoate
DTXSID70935673
Q27278852
propanoic acid, 2-[4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy]-, sodium salt (1:1)

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" No evidence of enantiomeric interaction at the pharmacokinetic level was detected."( Chiral pharmacokinetics and inversion of enantiomers of a new quinoxaline topoisomerase IIbeta poison in the rat.
Chan, KK; Chiu, MH; Covey, JM; Jiang, C; Zheng, H, 2002
)
0.31
"The pharmacokinetic parameters of XK469 following oral and IV administrations, respectively, were (mean+/-SD): C(max) 138+/-64 and 404 +/- 355 microg/ml; AUC(0-infinity) 2381 +/- 773 and 2854 +/- 1924 microg h/ml; and elimination half-life (T(1/2)) 12."( Bioavailability and pharmacokinetics of the investigational anticancer agent XK469 (NSC 698215) in rats following oral and intravenous administration.
Boinpally, RR; LoRusso, PM; Parchment, RE; Zhou, SL, 2005
)
0.33
" Blood samples were collected for pharmacokinetic studies."( A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.
Desai, AA; House, L; Innocenti, F; Karrison, T; Kindler, HL; Ramirez, J; Ratain, MJ; Singh, DA; Skoog, LA; Undevia, SD, 2008
)
0.35
" The observed interpatient pharmacokinetic variability should prompt investigation into the presence of genetic polymorphism in relevant metabolizing enzymes."( A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.
Desai, AA; House, L; Innocenti, F; Karrison, T; Kindler, HL; Ramirez, J; Ratain, MJ; Singh, DA; Skoog, LA; Undevia, SD, 2008
)
0.35

Bioavailability

ExcerptReferenceRelevance
"To determine the oral bioavailability of R-XK469, a water-soluble investigational anticancer agent undergoing phase I clinical trials as an intravenous product."( Bioavailability and pharmacokinetics of the investigational anticancer agent XK469 (NSC 698215) in rats following oral and intravenous administration.
Boinpally, RR; LoRusso, PM; Parchment, RE; Zhou, SL, 2005
)
0.33

Dosage Studied

ExcerptRelevanceReference
" Regardless of dosing schedule, conventional mice tolerated higher total doses than SCID or nu/nu mice did."( Preclinical antitumor activity of XK469 (NSC 656889).
Behrens, C; Corbett, TH; Demchik, L; Dzubow, J; Harrison, B; Knight, J; LoRusso, PM; Parchment, R; Polin, L; Trainor, G,
)
0.13
" dosing of S(-)XK469 at 10 mg/kg was monitored."( Chiral high-performance liquid chromatographic analysis of the enantiomers of XK469, a new antitumor agent, in plasma and urine.
Chan, KK; Covey, JM; Tosca, PJ; Turner, N; Zheng, H, 2002
)
0.31
"Together with the antitumor efficacy of oral XK469 shown in preclinical models and its schedule dependency, these results indicate the promise of developing an oral dosage form of R-XK469 for clinical development."( Bioavailability and pharmacokinetics of the investigational anticancer agent XK469 (NSC 698215) in rats following oral and intravenous administration.
Boinpally, RR; LoRusso, PM; Parchment, RE; Zhou, SL, 2005
)
0.33
" Based on the demonstration of a long half-life, the dosing schedule was subsequently amended to infusion on days 1, 3 and 5 of a 21-d cycle."( A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.
Desai, AA; House, L; Innocenti, F; Karrison, T; Kindler, HL; Ramirez, J; Ratain, MJ; Singh, DA; Skoog, LA; Undevia, SD, 2008
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (39)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (5.13)18.2507
2000's34 (87.18)29.6817
2010's3 (7.69)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.35 (24.57)
Research Supply Index3.83 (2.92)
Research Growth Index5.18 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (9.76%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (2.44%)4.05%
Observational0 (0.00%)0.25%
Other36 (87.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]